Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 62Neoplasms 7Neoplasms, Plasma Cell 6Recurrence 5Hematologic Neoplasms 4Renal Insufficiency 3Paraproteinemias 3Lymphoma 3Immunoglobulin Light-chain Amyloidosis 3Hematologic Diseases 3Smoldering Multiple Myeloma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms by Histologic Type 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leukemia 2Blood Protein Disorders 2Purpura 1Prostatic Neoplasms 1Neoplasm, Residual 1Nausea 1Natural Killer/T-cell Lymphoma 1Monoclonal Gammopathy of Undetermined Significance 1Macroglossia 1Lymphoproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Lymphadenopathy 1Leukemia, Plasma Cell 1Immunoproliferative Disorders 1

Interventions

Cyclophosphamide 9Pemetrexed 6pembrolizumab 5fludarabine 5Gemcitabine 5Cisplatin 5Carboplatin 5ponatinib 4atezolizumab 4Rituximab 4Dexamethasone 4Bevacizumab 4130-nm albumin-bound paclitaxel 4Sunitinib 3Melphalan 3Lutetium 3Doxorubicin 3Bortezomib 3tetulomab tetraxetan lu-177 2pralsetinib 2pomalidomide 2osimertinib 2napabucasin 2isatuximab 2fludarabine phosphate 2ficlatuzumab 2entrectinib 2entinostat 2durvalumab 2cobimetinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × isatuximab × Clear all
NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Hellenic Society of Hematology

Phase 2 Unknown
51 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡